Tolebrutinib Targets Chronic Lesions in MS Treatment: ACTRIMS 2025
A new analysis of Phase III clinical trial data presented at the ACTRIMS Forum 2025 in West Palm Beach, Florida, suggests that tolebrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), may be effective in multiple sclerosis (MS) with chronic active lesions.